Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03569527
Other study ID # HUM00127778
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 11, 2018
Est. completion date October 10, 2019

Study information

Verified date October 2019
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a parallel group pilot study comparing the efficacy green kiwifruit, prunes or psyllium on abdominal and bowel related symptoms in US patients with chronic constipation patients.


Description:

Chronic constipation and Irritable Bowel Syndrome with constipation are common gastrointestinal disorders which negatively impact quality of life, reduce work productivity, and account for significant direct and indirect costs. Patients with CC and IBS-C suffer with bowel symptoms such as reduced stool frequency, hard stool consistency, straining or a sensation of incomplete evacuation. Coupled with barriers which limit access to expensive prescription increasing concerns regarding the long-term safety of chronically dosed medications and, there has been an increasing demand for more "natural" solutions to a wide range of medical conditions, including CC and IBS-C. Green kiwifruit has long been used as a natural remedy to improve GI complaints. A growing body of literature supports the benefits of kiwifruit for gut health and in particular, abdominal discomfort and bowel regularity. In addition, patients are interested in dietary changes that could improve their symptoms The investigators propose a parallel group pilot study comparing the efficacy green kiwifruit, prunes or psyllium on abdominal and bowel related symptoms in US patients with chronic constipation patients. The investigators plan to recruit chronic constipation patients with or without pain. The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive kiwifruit (2 green kiwifruit per day, psyllium (12 g b.d./day, fiber=6g/day) or dried plums (50 g b.d., fiber=6 gm/day) for the 4 week intervention period. It is expected that Kiwifruit will offer greater efficacy than psyllium and prunes for abdominal and bowel symptoms in US patients with chronic constipation. This will be the first US data addressing the efficacy of Kiwifruit for abdominal and bowel symptoms in patients with chronic constipation.


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date October 10, 2019
Est. primary completion date October 10, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Presence of functional constipation according to modified ROME IV diagnostic criteria*5b i. Must include two or more of the following:

1. Straining more than 25% of defecations

2. Lumpy or hard stools more than 25% of defecations

3. Sensation of incomplete evacuation more than 25% of defecations

4. Sensation of anorectal obstruction/blockage more than 25% of defecations

5. Manual manoeuvres to facilitate more than 25% of defecations (e.g. digital evacuation, support of pelvic floor)

6. Fewer than three defecations per week ii. Loose stools are rarely present without the use of laxatives * Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis For the purposes of this study, patients with abdominal pain will be included, but patients with severe pain (defined as average daily abdominal pain score of 7 or higher during the screening period) will be excluded. Patients with an appropriate level of GI symptoms despite taking stable doses (>3 months) of SSRI's, tricyclics or SNRIs will be allowed to enroll.

Exclusion Criteria:

Potential participants will be excluded if they have alarm features (GI bleeding, weight loss, unexplained iron deficiency anaemia, significant family history of colorectal cancer or IBD), anal fissures, significant chronic diseases (cardiovascular, cancer, renal failure, inflammatory bowel disease), previous gastrointestinal surgery (except appendectomy or cholecystectomy), neurological diseases (e.g. multiple sclerosis, spinal cord injury, CVA).

Patients taking opiates will not be eligible to participate. Women who are pregnant, breastfeeding or planning a pregnancy in the 2 months post selection (trial period) will be excluded.

As above, patients with severe IBS symptoms will be excluded (defined as average daily abdominal pain score of 7 or higher during the screening period).

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Kiwifruit
The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive kiwifruit (2 green kiwifruit per day for the 4 week intervention period.
Fiber
The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive psyllium fiber (24 g/day, fiber=6g/day) for the 4 week intervention period.
Prunes
The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive prunes/dried plums (100g, fiber=6 g/day) for the 4 week intervention period.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary : Change in complete spontaneous bowel movement (CSBM) Complete spontaneous bowel movement will be recorded. This will be compared to the baseline, run-in periods, and follow-up period. 8 weeks
Secondary Change in SBM (spontaneous bowel movements) Spontaneous bowel movements will be recorded. This will be compared to the baseline, run-in periods, and follow-up period. 8 weeks
Secondary stool consistency Bristol stool form scale (1-7, lower scores are consistent with constipation; higher scores are consistent with diarrhea) will be recorded. This will be averaged and compared to the baseline, run-in period, and follow-up period. 8 weeks
Secondary straining 5 point Likert scale for straining will be recorded (1-5, lower scores= less straining, higher scores = more straining). This will be averaged and compared to the baseline, run-in periods, and follow-up period. 8 weeks
Secondary abdominal pain Daily score (0-10) for abdominal pain will be recorded (0=no pain, 10= severe pain). This will be averaged and compared to the baseline, run-in periods, and follow-up period. 8 weeks
Secondary abdominal discomfort Daily score (0-10) for abdominal discomfort will be recorded (0=no pain, 10= severe pain). This will be averaged and compared to the baseline, run-in periods, and follow-up period. 8 weeks
Secondary bloating Daily score (0-10) for abdominal bloating will be recorded (0=no pain, 10= severe pain). This will be averaged and compared to the baseline, run-in periods, and follow-up period. 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT05980988 - Effectiveness and Safety of Probiotic in Regulating Chronic Constipation N/A
Recruiting NCT03819062 - Sacral Neuromodulation as Treatment for Chronic Constipation N/A
Completed NCT00730171 - An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT00765882 - Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation Phase 3
Completed NCT00354575 - Effect of Chinese Herb on Chronic Constipation for Residents in Long-Term Care Units Phase 2
Active, not recruiting NCT03119584 - Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation Phase 4
Completed NCT00765999 - An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT01793753 - Effect of Propofol on Internal Anal Sphincter Pressure During ARM N/A
Completed NCT00746200 - Acupuncture for Chronic Constipation Phase 3
Enrolling by invitation NCT00671684 - Endoscopic Mucosal Resection (EMR) for Diagnosis of Hirschsprung's Disease Phase 1/Phase 2
Completed NCT00391820 - Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial) Phase 2
Completed NCT00404040 - Movicol in Childhood Constipation (ProMotion Study) Phase 2
Completed NCT02281630 - Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC) Phase 2
Completed NCT00256984 - Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS) Phase 4
Recruiting NCT05192317 - Administration of a Natural Molecular Complex in Functional Chronic Constipation N/A
Active, not recruiting NCT05202028 - The Efficacy of Massage and Reflexology Applications in Children With Cerebral Palsy N/A
Completed NCT05734859 - Drinking Effect of Electrolyzed Alkaline Reduced Water on Functional Constipation N/A
Completed NCT01007123 - Study of A3309 in Patients With Chronic Idiopathic Constipation Phase 2
Completed NCT00402337 - Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation Phase 2
Completed NCT02961556 - General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation Phase 3